<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Hologic's Breast Health Rebound in Motion: How to Play the Stock Now?</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Hologic's Breast Health Rebound in Motion: How to Play the Stock Now?</h1>
  <ul>
<li>DHR, which fell 7.3% and 10.6%, respectively.</li>
<li>In the last six months, shares of HOLX have risen 4.2% against the industry’s 7% decline and the Zacks Medical sector’s 6.3% fall.</li>
<li>Based on planned mitigation efforts, the company anticipates direct tariff costs to be nearly $10 million-$12 million per quarter from fiscal 2026, down from the initial $20 million-$25 million forecast.</li>
<li>With only about 12% market penetration, Hologic expects Biotheranostics to emerge as a key growth platform in the future.</li>
<li>Hologic’s latest innovation, the Genius AI Detection PRO, builds on its flagship Genius AI Detection 2.0 Solution, featuring advanced workflows, enhanced diagnostic accuracy and up to 24% reduction in radiologists’ overa</li>
<li>To derisk itself from future geopolitical turmoil, Hologic had lowered its China revenue forecast by $20 million, now expecting only $50 million.</li>
<li>In addition, the team rolled out a new strategy to upgrade older end-of-life gantries, which is set to gain more traction in the fourth quarter and into 2026.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/hologics-breast-health-rebound-motion-130000470.html">Source</a> · 2025-09-15T13:00:00+00:00</p>
</body>
</html>